IL103229A - Imidazolylmethyl-pyridine derivatives their preparation and pharmaceutical compositions containing them - Google Patents
Imidazolylmethyl-pyridine derivatives their preparation and pharmaceutical compositions containing themInfo
- Publication number
- IL103229A IL103229A IL10322992A IL10322992A IL103229A IL 103229 A IL103229 A IL 103229A IL 10322992 A IL10322992 A IL 10322992A IL 10322992 A IL10322992 A IL 10322992A IL 103229 A IL103229 A IL 103229A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- alkyl
- acid addition
- free base
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Luminescent Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compounds of the formula I <IMAGE> in which R1 denotes alkyl having 1 to 4 carbon atoms, halogen having an atomic number of 9 to 35 or amino which is optionally mono- or disubstituted by alkyl having 1 to 4 carbon atoms, R2 and R3 independently of one another stand for hydrogen or alkyl having 1 to 4 carbon atoms and R4 denotes hydrogen, hydroxyl, alkyl or alkoxy each having 1 to 4 carbon atoms or halogen having an atomic number of 9 to 35, in the form of the free base or in acid addition salt form, can be used for the treatment of senile dementia and Alzheimer's disease and as antidepressant.
Description
Imidazolylmethyl -pyridine derivatives, their preparation and pharmaceutical compositions containing them SANDOZ A.G.
C. 87025 CASE 100-7825 IMIDAZOLYLMETHYL-PYRIDINES The present invention relates to imidazolylmethyl-pyridines production, their use as pharmaceuticals and pharmaceutical compositions containing them.
More particularly the present invention provides compounds formula I, wherein Rj. is alkyl (1-4 C), halogen with an atomic number of 9 to 35 or amino optionally mono- or disubstituted by alkyl (1-4 C), R2 and R3 independently of one another are hydrogen or alkyl (1-4 C) and R4 is hydrogen, hydroxy, alkyl (1-4 C), alkoxy (1-4 C) or halogen with an atomic number of 9 to 35, in free base or acid addition salt form, hereinafter referred to as new compounds. - 2 - 100-7825 Insofar as above-defined alkyl or alkoxy groups are present in the new compounds, these preferably have one or two carbon atoms and especially signify methyl or methoxy.
The imidazolylmethyl radical is preferably in position 2 of the pyridine.
Rj. is preferably methyl. R2 and R3 are preferably each hydrogen. R4 is preferably hydrogen. The compound of Example 1 is preferred.
In a particular group of new compounds, Rj. is alkyl (1-4 C), R2 and R3 independently of one another are hydrogen or alkyl (1-4 C) and R4 is hydrogen, alkyl (1-4 C) or halogen with an atomic number of 9 to 35.
In accordance with the invention, the new compounds are obtained by reacting a compound of formula II, wherein R4 is defined as above, and X is halogen, with a compound of formula III, wherein Rj. , R2 and R3 are defined as above, - 3 - 100-7825 and recovering the resulting compound of formula I in free base form or in acid addition salt form.
The reaction of the compound of formula II with the compound of formula II may take place in known manner, in a solvent which is inert under the reaction conditions, e.g. in dimethylformamide or a lower alcohol. In formula II, X is preferably chlorine.
Working up of the reaction mixtures obtained and purification of the compounds of formula I thus produced may take place in accordance with known methods.
The compounds of formula I may be present in free form or in the form of their acid addition salts. Acid addition salts may be produced from the free bases in known manner, and vice versa.
The starting compounds of formulae II and III are known or may be produced in accordance with known processes, resp. analogously to known processes.
The compounds of formula I and their physiologically acceptable salts, hereinafter referred to as compounds according to the invention, exhibit interesting pharmacological activities and may therefore be used as pharmaceuticals.
In the sleep/wake cycle of the long-term implanted rat [for the method, see J.-M. Vigouret et al., J. Pharmacol 10, 503 (1978)], the compounds according to the invention when administered at 1 to 100 mg/kg p.o. effect an increase in vigilance by prolonging the wake phases. 103229/2 The present invention relates to imidazolylmethyl-pyridines, their production, their use as pharmaceuticals and pharmaceutical compositions containing them.
USP 4,230,714 discloses imidazolylmethyl-pyridines and -quinolines unsubstituted at the 2-positio of the imidazole moiety. Whereas these compounds are useful in treating ischemic heart disease stroke and migraine, the 2-substituted imidazoles of the present invention exhibit an unexpecte pharmacological profile indicative of central activity.
More particularly the present invention provides compounds formula I, wherein derlined . IX.1992 C) in free base or acid addition salt form, hereinafter referred to as new compounds. - 5 - 100-7825 In accordance with the foregoing, the present invention also provides a compound according to the invention, for use as a pharmaceutical, e.g. for the treatment of senile dementia, Alzheimer's disease and further degenerative diseases such as Huntington's chorea, Morbus Parkinson, Steel-Richardson syndrome, tardive dyskinesias, hyperkinesia, acute confusion disorders, Down's syndrome, myasthenia gravis and Friedrich's ataxia, and for the treatment of depression.
The present invention furthermore provides a pharmaceutical composition comprising a compound according to the invention in association with at least one pharmaceutical carrier or diluent. Such compositions may be manufactured in conventional manner. Unit dosage forms contain, for example, from about 0.25 mg to about 50 mg of a compound according to this invention.
The following examples illustrate the invention. The temperatures are given in degrees Celsius and are uncorrected. - 6 - 100-7825 EXAMPLE 1; [2-(2-methylimidazol-l-yl)methyl]pyridine 9.7 g (75 mM) of 2-(chloromethyl)pyridine and 42 g (512 mM) of 2-methyl-imidazole are suspended in 40 ml dimethylformamide, then stirred for 3 hours at 105 °. The dimethylformamide is distilled off and the crystalline residue is diluted with ethyl acetate and a little hexane. Following filtration, the mother solution is concentrated by evaporation and the dimethylformamide distilled off, and then shaken out several times between water and methylene chloride. 10.3 g of the oily title compound are obtained. 9.3 g of the obtained base in ethanol are mixed with 12.7 g of fumaric acid. The resulting bis(base)-tris(hydrogen fumarate)crystallizes from ethanol/ethyl acetate and is recrystallized once from ethanol/ethyl acetate. It is uniform upon thin-layer chromatography and melts at 109 - 110 °.
The following [2-(imidazol-l-yl)methyl] pyridines are produced analogously to example 1: fumarate dihydrochloride - 7 - 100-7825 well as the following [4-(imidazol-l-yl)methyl]pyridine: fumarate
Claims (9)
1. A process for the production of a compound of formula I, wherein Ri is alkyl (1-4 C) , halogen with an atomic number of 9 to 35 or amino optionally mono- or disubstituted by alkyl (1-4 C) , underlined R2 and R3 independently of one another are hydrogen or alkyl 21. IX.1992 (1-4 C) and R4 is hydrogen, hydroxy, alkyl (1-4 C), alkoxy (1-4 C) or halogen with an atomic number of 9 to 35, in free base or acid addition salt form, which includes the step of reacting a compound of formula II, wherein R4 is defined as above, and X is halogen, with a compound of formula III, 100-7825 wherein Ri , R2 and R3 are defined as above, and recovering the resulting compound of formula I in free base form or in acid addition salt form.
2. A process for the production of a compound of formula I in free base form or in acid addition salt form, substantially as hereinbefore described with reference to the examples.
3. A compound of formula I in free base form or acid addition salt form, whenever produced by the process of claim 1.
4. A compound of formula I in free base form or acid addition salt form, as defined in claim 1.
5. A compound of claim 4 wherein Rx is alkyl (1-4 C), R2 and R3 independently of one another are hydrogen or alkyl (1-4 C) and R4 is hydrogen, alkyl (1-4 C) or halogen with an atomic number of 9 to 35, in free base or acid addition salt form.
6. A compound of claim 4 which is the [2-(2-methylimidazol- l-yl)methyl]pyridine, in free base or acid addition salt form. - 10 - 100-7825
7. A compound of claim 4 wherein — Ri = CH3, R2 = H, R3 = H, R = 6-CH3 , or — Rj = CH3 , Rj = CH3 , 3 = H, R4 = H, or — R]_ = CH3 R2 — H t R3 = CH3 , Rij β H, and the imidazolylmethyl group is in position 2, or — Ri = CH3 , R2 = H, R3 = H, R4 = H and the imidazolylmethyl group is in position 4, in free base or acid addition salt form.
8. A compound of any one of claims 3 to 7 in physiologically acceptable form, for use as a pharmaceutical.
9. A compound of any one of claims 3 to 7 in physiologically acceptable form, for use in the treatment of senile dementia, Alzheimer's disease, Huntington's chorea, Morbus Parkinson, Steel-Richardson syndrome, tardive dyskinesia, hyperkinesia, acute confusion disorders, Down's syndrome, myasthenia gravis or Friedrich's ataxia, or in the treatment of depression. A pharmaceutical composition comprising a compound according to any one of claims 3 to 7 in physiologically acceptable form, in association with a pharmaceutical carrier or diluent. For the Applicants
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4131584A DE4131584A1 (en) | 1991-09-23 | 1991-09-23 | IMIDAZOLYLMETHYL-PYRIDINE, THEIR PRODUCTION AND USE AS A PHARMACEUTICAL |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL103229A0 IL103229A0 (en) | 1993-02-21 |
| IL103229A true IL103229A (en) | 1996-09-12 |
Family
ID=6441240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10322992A IL103229A (en) | 1991-09-23 | 1992-09-21 | Imidazolylmethyl-pyridine derivatives their preparation and pharmaceutical compositions containing them |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP0534904B1 (en) |
| JP (1) | JP2568356B2 (en) |
| KR (1) | KR100254085B1 (en) |
| AT (1) | ATE144509T1 (en) |
| AU (1) | AU650569B2 (en) |
| CA (1) | CA2078700C (en) |
| CZ (1) | CZ281675B6 (en) |
| DE (2) | DE4131584A1 (en) |
| DK (1) | DK0534904T3 (en) |
| ES (1) | ES2092666T3 (en) |
| FI (1) | FI103887B (en) |
| GR (1) | GR3021444T3 (en) |
| HU (2) | HUT61993A (en) |
| IL (1) | IL103229A (en) |
| MX (1) | MX9205365A (en) |
| MY (1) | MY110450A (en) |
| NO (1) | NO301162B1 (en) |
| NZ (1) | NZ244420A (en) |
| RO (1) | RO109337B1 (en) |
| RU (1) | RU2058312C1 (en) |
| SG (1) | SG43079A1 (en) |
| SK (1) | SK289692A3 (en) |
| TW (1) | TW222630B (en) |
| ZA (1) | ZA927279B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10165349A (en) * | 1996-12-06 | 1998-06-23 | Matsushita Electric Ind Co Ltd | Dish washer |
| DE10000161A1 (en) * | 2000-01-06 | 2001-07-19 | Boehringer Ingelheim Pharma | Determining test substances that inhibit protease, involves incubating cells expressing fusion protein having substrate with cleavage site for protease and reporter, measuring cleaved reporter and comparing with standard |
| GB0009037D0 (en) * | 2000-04-13 | 2000-05-31 | Novartis Ag | Organic compounds |
| NZ565763A (en) * | 2005-07-29 | 2010-12-24 | Vanda Pharmaceuticals Inc | Method of improving wakefulness |
| JP5044572B2 (en) * | 2006-02-13 | 2012-10-10 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Stable dosage formulation of imidazolylalkyl-pyridine |
| WO2009097416A1 (en) * | 2008-01-29 | 2009-08-06 | Vanda Pharmaceuticals, Inc. | Imidazolylalkyl- pyridines as dbh inhibitors |
| KR20110071014A (en) | 2008-10-17 | 2011-06-27 | 위스콘신 얼럼나이 리서어치 화운데이션 | Method of making biologically active alpha-beta peptides |
| US9394290B2 (en) * | 2010-10-21 | 2016-07-19 | Universitaet Des Saarlandes Campus Saarbruecken | Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases |
| JP2020520952A (en) * | 2017-05-22 | 2020-07-16 | トーリー パインズ インスティテュート フォー モレキュラー スタディーズＴｏｒｒｅｙ Ｐｉｎｅｓ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｍｏｌｅｃｕｌａｒ Ｓｔｕｄｉｅｓ | Compositions, methods of use and methods of treatment |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2862340D1 (en) * | 1978-02-01 | 1983-11-24 | Wellcome Found | Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations thereof |
| GB2028317B (en) * | 1978-08-15 | 1982-11-10 | Pfizer Ltd | 2-(imidazol-1-ylmethyl)-pyridine and -quinoline thromboxane synthetase inhibitors |
| US4634711A (en) * | 1985-08-02 | 1987-01-06 | Smithkline Beckman Corporation | Pyridylalkyl imidazole-2-thiols |
| DE3811574A1 (en) * | 1988-03-31 | 1989-10-19 | Schering Ag | N-SUBSTITUTED IMIDAZOLES, METHODS FOR THEIR PRODUCTION AND THEIR USE IN MEDICINAL PRODUCTS |
-
1991
- 1991-09-23 DE DE4131584A patent/DE4131584A1/en not_active Withdrawn
-
1992
- 1992-09-09 HU HU9202886A patent/HUT61993A/en unknown
- 1992-09-18 MY MYPI92001673A patent/MY110450A/en unknown
- 1992-09-21 AU AU25226/92A patent/AU650569B2/en not_active Ceased
- 1992-09-21 IL IL10322992A patent/IL103229A/en not_active IP Right Cessation
- 1992-09-21 FI FI924233A patent/FI103887B/en not_active IP Right Cessation
- 1992-09-21 AT AT92810719T patent/ATE144509T1/en active
- 1992-09-21 NZ NZ244420A patent/NZ244420A/en not_active IP Right Cessation
- 1992-09-21 NO NO923653A patent/NO301162B1/en not_active IP Right Cessation
- 1992-09-21 SG SG1996003366A patent/SG43079A1/en unknown
- 1992-09-21 EP EP92810719A patent/EP0534904B1/en not_active Expired - Lifetime
- 1992-09-21 DK DK92810719.2T patent/DK0534904T3/en active
- 1992-09-21 CZ CS922896A patent/CZ281675B6/en not_active IP Right Cessation
- 1992-09-21 CA CA002078700A patent/CA2078700C/en not_active Expired - Fee Related
- 1992-09-21 SK SK2896-92A patent/SK289692A3/en not_active IP Right Cessation
- 1992-09-21 DE DE59207425T patent/DE59207425D1/en not_active Expired - Lifetime
- 1992-09-21 ES ES92810719T patent/ES2092666T3/en not_active Expired - Lifetime
- 1992-09-22 KR KR1019920017228A patent/KR100254085B1/en not_active IP Right Cessation
- 1992-09-22 MX MX9205365A patent/MX9205365A/en unknown
- 1992-09-22 RO RO92-01218A patent/RO109337B1/en unknown
- 1992-09-22 RU SU925052552A patent/RU2058312C1/en active
- 1992-09-22 JP JP4252692A patent/JP2568356B2/en not_active Expired - Fee Related
- 1992-09-23 ZA ZA927279A patent/ZA927279B/en unknown
- 1992-09-24 TW TW081107550A patent/TW222630B/zh active
-
1995
- 1995-06-13 HU HU95P/P00198P patent/HU211261A9/en unknown
-
1996
- 1996-10-24 GR GR960402593T patent/GR3021444T3/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1535379A3 (en) | Method of producing 5-substituted 2,4-diaminopyrimidines or their acid-additive salts | |
| HU199425B (en) | Process for producing alpha-alkyl-/4-amino-3-quinolinyl/-methanols and 1-square brackets open 4-/aralkylamino/-3-quinolinyl square brackets closed -alkanones, as well as pharmaceutical compositions comprising such compounds as active ingredient | |
| EP0070562B1 (en) | Ergoline derivatives, processes for their preparation and pharmaceutical compositions containing them | |
| JPH0867670A (en) | Use of substituted 4-phenyl-6-aminonicotinic acid derivativeas drug | |
| JPS61155358A (en) | Diallylbutyric acid derivative and production thereof | |
| EP0483932A1 (en) | Process for the preparation of piperazine derivatives | |
| IE62936B1 (en) | Arylthiazolylimidazoles as 5ht3 antagonists | |
| IL103229A (en) | Imidazolylmethyl-pyridine derivatives their preparation and pharmaceutical compositions containing them | |
| US5166181A (en) | Halogenoalkylphenyl-alcohols, ketones and hydrates thereof | |
| EP4206197A1 (en) | Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method | |
| DE3851856T2 (en) | 1,4-Dihydropyridine derivatives and pharmaceutical compositions containing them. | |
| DE69224507T2 (en) | Beta-oxo-beta-benzene propanthioamide derivatives | |
| FR2549061A1 (en) | SPIROSUCCINIMIDE DERIVATIVES USEFUL AS MEDICAMENTS | |
| US5258383A (en) | DC-89 derivatives | |
| US4556739A (en) | 3,4-Dialkoxy-2-alkylcarbonyl analino compounds | |
| US20020019427A1 (en) | Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof | |
| US20020061919A1 (en) | Process for the preparation of 1,2,3,9-tetrahydro-9-methyl-3-{(2-methyl-1h-imidazol-1-yl)methyl}-4h-carbazol-4-one | |
| US5635521A (en) | Imidazolylmethyl-pyridines | |
| HU197878B (en) | Process for producing guanidino-benzoic acid esters and pharmaceutical compositions containing them | |
| GB2171997A (en) | 4-Amino-6,7-dimethoxy-2-Piperazin-1-ylquinazoline derivatives | |
| ES2912409T3 (en) | Intermediates and processes for the preparation of linagliptin and its salts | |
| CA1323876C (en) | Dihydropyridine derivatives and pharmaceutical composition thereof | |
| US4843085A (en) | Pyridine derivatives, process for production thereof and pharmaceutical compositions useful as anti-arhytmics | |
| GB2101587A (en) | Methylenedioxybenzene derivatives. | |
| EP0122376B1 (en) | Anticholinesterase pyridine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| HC | Change of name of proprietor(s) | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |